Bedel Financial Consulting, Inc. Novartis Ag Transaction History

Bedel Financial Consulting, Inc.

$716 Million
Q3 2024

A detailed history of Bedel Financial Consulting, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Bedel Financial Consulting, Inc. holds 4,445 shares of NVS stock, worth $437,610. This represents 0.07% of its overall portfolio holdings.

Number of Shares

4,445

Previous 4,445 -0.0%

Holding current value

$437,610

Previous $473,000 8.03%

% of portfolio

0.07%

Previous 0.07%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$92.52 - $104.91 $14,155 - $16,051	153 Added 3.56%	4,445 $448,000
Q1 2023 May 02, 2023	BUY	$80.03 - $92.81 $26,730 - $30,998	334 Added 8.44%	4,292 $394,000
Q4 2022 Feb 07, 2023	BUY	$75.55 - $92.52 $34,148 - $41,819	452 Added 12.89%	3,958 $359,000
Q3 2022 Nov 08, 2022	BUY	$74.61 - $87.26 $261,582 - $305,933	3,506 New	3,506 $287,000
Q2 2022 Aug 04, 2022	SELL	$80.52 - $93.75 $128,912 - $150,093	-1,601 Closed	0 $0
Q1 2022 Apr 19, 2022	BUY	$80.11 - $90.62 $3,444 - $3,896	43 Added 2.76%	1,601 $141,000
Q4 2021 Jan 11, 2022	BUY	$79.7 - $88.13 $4,782 - $5,287	60 Added 4.01%	1,558 $136,000
Q1 2021 Apr 26, 2021	BUY	$83.5 - $98.47 $45,340 - $53,469	543 Added 56.86%	1,498 $128,000
Q4 2020 Feb 02, 2021	SELL	$78.07 - $94.43 $468 - $566	-6 Reduced 0.62%	955 $90,000
Q1 2020 May 06, 2020	BUY	$70.67 - $99.01 $7,491 - $10,495	106 Added 12.4%	961 $79,000
Q2 2019 Aug 01, 2019	SELL	$75.4 - $92.8 $377 - $464	-5 Reduced 0.58%	855 $78,000
Q1 2019 May 02, 2019	BUY	$75.32 - $86.15 $376 - $430	5 Added 0.58%	860 $83,000
Q1 2018 May 03, 2018	BUY	$70.39 - $84.15 $60,183 - $71,948	855 New	855 $69,000

Others Institutions Holding NVS

# of Institutions

1,437

Shares Held

131M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $212B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.

Account

Bedel Financial Consulting, Inc. Novartis Ag Transaction History